Dapagliflozin (2S)-1,2-propanediol, hydrate

• CAT Number: I005695
• CAS Number: 960404-48-2
• Molecular Formula: C24H35ClO9
• Molecular Weight: 502.98
• Purity: ≥95%
• Target: SGLT2
• Solubility: 10 mM in DMSO
• Storage: -20°C
• IUPAC Name: (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;(2S)-propane-1,2-diol;hydrate
• InChI: InChI=1S/C21H25ClO6.C3H8O2.H2O/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4;/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3;1H2/t17-,18-,19+,20-,21+;3-;/m10./s1
• InChIKey: GOADIQFWSVMMRJ-UPGAGZFNSA-N
• SMILES: CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O

Dapagliflozin (CAT: I005695), also known as (2S)-1,2-propanediol hydrate, is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus. By inhibiting SGLT2, dapagliflozin reduces the reabsorption of glucose in the kidneys, leading to increased urinary glucose excretion and lower blood glucose levels. This mechanism of action promotes glycemic control and helps manage hyperglycemia in patients with type 2 diabetes.

Reference

1. Ghosh, et al. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. Journal of Clinical Pharmacology (2012), 52(4), 457-461.
2. Bolinder, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. Journal of Clinical Endocrinology and Metabolism (2012), 97(3), 1020-1031.
3. Rosenstock J, et al. Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy. Diabetes Care. 2012 Jul;35(7):1473-8.
4. Bailey CJ, et al. Dapagliflozin monotherapy in drug-nave patients with diabetes: a randomized-controlled trial of low-dose range(). Diabetes Obes Metab. 2012 Jul 6;9999(9999). doi: 10.1111/j.1463-1326.2012.01659.x.